Bendell, Johanna C <br/><br/>
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer.  [electronic resource] 

 -  Investigational new drugs  Aug 2014 
 - 682-90 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-014-0088-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents, Phytogenic--therapeutic use<br/>Camptothecin--analogs & derivatives<br/>Colorectal Neoplasms--drug therapy<br/>Disease Progression<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Irinotecan<br/>Male<br/>Maximum Tolerated Dose<br/>Membrane Glycoproteins--antagonists & inhibitors<br/>Middle Aged<br/>Young Adult